Clinical trials involving vaccination of interferon gamma release assay (IGRA) positive people are underway [5], demonstrating the requirement for vaccines for deployment in those potentially infected with TB and highlighting the need for relevant models to enable the assessment of vaccine efficacy under these conditions. This evidence concerns the gene IFNG and tuberculosis.